Heterologous versus homologous primary and booster COVID-19 vaccination do not increase flare rate in patients with psoriasis and/or psoriatic arthritis: Insights from a real-life, multicenter, case-control study
J Eur Acad Dermatol Venereol
.
2023 Jun;37(6):e693-e694.
doi: 10.1111/jdv.18943.
Epub 2023 Feb 15.
Authors
Santo Raffaele Mercuri
1
,
Alessia Pacifico
2
,
Piergiorgio Malagoli
3
,
Vittoria Giulia Bianchi
1
,
Fabrizio Ernesto Pregliasco
4
5
,
Massimo Del Fabbro
4
6
7
,
Giovanni Damiani
1
6
7
Affiliations
1
Unit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy.
2
Clinical Dermatology Department, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
3
Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.
4
IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy.
5
Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
6
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
7
Italian Center of Precision Medicine and Chronic Inflammation, Milan, Italy.
PMID:
36734591
DOI:
10.1111/jdv.18943
No abstract available
Publication types
Multicenter Study
Letter
MeSH terms
Arthritis, Psoriatic*
COVID-19 Vaccines
COVID-19* / prevention & control
Case-Control Studies
Humans
Psoriasis* / drug therapy
Substances
COVID-19 Vaccines